Cardio Diagnostics (NASDAQ:CDIO) versus Black Diamond Therapeutics (NASDAQ:BDTX) Head-To-Head Contrast

Black Diamond Therapeutics (NASDAQ:BDTX) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Valuation & Earnings

This table compares Black Diamond Therapeutics and Cardio Diagnostics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70.00 million	1.74	$22.37 million	($0.75)	-2.83
Cardio Diagnostics	$14,450.00	381.01	-$6.50 million	($2.92)	-0.64

Black Diamond Therapeutics has higher revenue and earnings than Cardio Diagnostics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Black Diamond Therapeutics has a beta of 3.31, indicating that its share price is 231% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500.

Profitability

This table compares Black Diamond Therapeutics and Cardio Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

Analyst Recommendations

This is a summary of current ratings and price targets for Black Diamond Therapeutics and Cardio Diagnostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1	2	8	0	2.64
Cardio Diagnostics	1	0	0	0	1.00

Black Diamond Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 383.49%. Given Black Diamond Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Black Diamond Therapeutics is more favorable than Cardio Diagnostics.

Insider and Institutional Ownership

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Black Diamond Therapeutics beats Cardio Diagnostics on 12 of the 14 factors compared between the two stocks.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.